This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciornei, C. D.
Right arrow Articles by Bodelsson, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciornei, C. D.
Right arrow Articles by Bodelsson, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2005, p. 2845-2850, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.2845-2850.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Antimicrobial and Chemoattractant Activity, Lipopolysaccharide Neutralization, Cytotoxicity, and Inhibition by Serum of Analogs of Human Cathelicidin LL-37

Cristina D. Ciornei,1,{dagger} Thorgerdur Sigurdardóttir,1 Artur Schmidtchen,2 and Mikael Bodelsson1*

Department of Anesthesiology and Intensive Care,1 Department of Dermatology and Venereology, Lund University, Lund, Sweden2

Received 16 December 2004/ Returned for modification 13 January 2005/ Accepted 3 April 2005

Antimicrobial peptides have been evaluated in vitro and in vivo as alternatives to conventional antibiotics. Apart from being antimicrobial, the native human cathelicidin-derived peptide LL-37 (amino acids [aa] 104 to 140 of the human cathelicidin antimicrobial peptide) also binds and neutralizes bacterial lipopolysaccharide (LPS) and might therefore have beneficial effects in the treatment of septic shock. However, clinical trials have been hampered by indications of toxic effects of LL-37 on mammalian cells and evidence that its antimicrobial effects are inhibited by serum. For the present study, LL-37 was compared to two less hydrophobic fragments obtained by N-terminal truncation, named 106 (aa 106 to 140) and 110 (aa 110 to 140), and to a previously described more hydrophobic variant, the 18-mer LLKKK, concerning antimicrobial properties, lipopolysaccharide neutralization, toxicity against human erythrocytes and cultured vascular smooth muscle cells, chemotactic activity, and inhibition by serum. LL-37, fragments 106 and 110, and the 18-mer LLKKK inhibited the growth of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans in a radial diffusion assay, inhibited lipopolysaccharide-induced vascular nitric oxide production, and attracted neutrophil granulocytes similarly. While fragments 106 and 110 caused less hemolysis and DNA fragmentation in cultured cells than did LL-37, the 18-mer LLKKK induced severe hemolysis. The antibacterial effect of fragments 106 and 110 was not affected by serum, while the effect of LL-37 was reduced. We concluded that the removal of N-terminal hydrophobic amino acids from LL-37 decreases its cytotoxicity as well as its inhibition by serum without negatively affecting its antimicrobial or LPS-neutralizing action. Such LL-37-derived peptides may thus be beneficial for the treatment of patients with sepsis.

* Corresponding author. Mailing address: Department of Anesthesia and Intensive Care, University Hospital, Getingevägen 4, SE-221 85 Lund, Sweden. Phone: 46 46 17 19 49. Fax: 46 46 17 60 50. E-mail: mikael.bodelsson{at}anest.lu.se.

{dagger} Present address: Department of Surgery, Malmö University Hospital, Malmö, Sweden.

Antimicrobial Agents and Chemotherapy, July 2005, p. 2845-2850, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.2845-2850.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Mader, J. S., Mookherjee, N., Hancock, R. E.W., Bleackley, R. C. (2009). The Human Host Defense Peptide LL-37 Induces Apoptosis in a Calpain- and Apoptosis-Inducing Factor-Dependent Manner Involving Bax Activity. Mol Cancer Res 7: 689-702 [Abstract] [Full Text]  
  • Stromstedt, A. A., Pasupuleti, M., Schmidtchen, A., Malmsten, M. (2009). Evaluation of Strategies for Improving Proteolytic Resistance of Antimicrobial Peptides by Using Variants of EFK17, an Internal Segment of LL-37. Antimicrob. Agents Chemother. 53: 593-602 [Abstract] [Full Text]  
  • Tanaka, T., Kokuryu, Y., Matsunaga, T. (2008). Novel Method for Selection of Antimicrobial Peptides from a Phage Display Library by Use of Bacterial Magnetic Particles. Appl. Environ. Microbiol. 74: 7600-7606 [Abstract] [Full Text]  
  • Bu, H.-F., Wang, X., Zhu, Y.-Q., Williams, R. Y., Hsueh, W., Zheng, X., Rozenfeld, R. A., Zuo, X.-L., Tan, X.-D. (2006). Lysozyme-Modified Probiotic Components Protect Rats against Polymicrobial Sepsis: Role of Macrophages and Cathelicidin-Related Innate Immunity. J. Immunol. 177: 8767-8776 [Abstract] [Full Text]  
  • Mookherjee, N., Wilson, H. L., Doria, S., Popowych, Y., Falsafi, R., Yu, J., Li, Y., Veatch, S., Roche, F. M., Brown, K. L., Brinkman, F. S. L., Hokamp, K., Potter, A., Babiuk, L. A., Griebel, P. J., Hancock, R. E. W. (2006). Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. J. Leukoc. Biol. 80: 1563-1574 [Abstract] [Full Text]  
  • Andra, J., Gutsmann, T., Garidel, P., Brandenburg, K. (2006). Invited review: Mechanisms of endotoxin neutralization by synthetic cationic compounds. Innate Immunity 12: 261-277 [Abstract]  
  • Sigurdardottir, T., Andersson, P., Davoudi, M., Malmsten, M., Schmidtchen, A., Bodelsson, M. (2006). In Silico Identification and Biological Evaluation of Antimicrobial Peptides Based on Human Cathelicidin LL-37.. Antimicrob. Agents Chemother. 50: 2983-2989 [Abstract] [Full Text]  
  • Motzkus, D., Schulz-Maronde, S., Heitland, A., Schulz, A., Forssmann, W.-G., Jubner, M., Maronde, E. (2006). The novel {beta}-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. FASEB J. 20: 1701-1702 [Abstract] [Full Text]  
  • Moy, T. I., Ball, A. R., Anklesaria, Z., Casadei, G., Lewis, K., Ausubel, F. M. (2006). From the Cover: Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. USA 103: 10414-10419 [Abstract] [Full Text]  
  • Giacometti, A., Cirioni, O., Ghiselli, R., Mocchegiani, F., Orlando, F., Silvestri, C., Bozzi, A., Di Giulio, A., Luzi, C., Mangoni, M. L., Barra, D., Saba, V., Scalise, G., Rinaldi, A. C. (2006). Interaction of antimicrobial Peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria.. Antimicrob. Agents Chemother. 50: 2478-2486 [Abstract] [Full Text]  
  • Mookherjee, N., Brown, K. L., Bowdish, D. M. E., Doria, S., Falsafi, R., Hokamp, K., Roche, F. M., Mu, R., Doho, G. H., Pistolic, J., Powers, J.-P., Bryan, J., Brinkman, F. S. L., Hancock, R. E. W. (2006). Modulation of the TLR-Mediated Inflammatory Response by the Endogenous Human Host Defense Peptide LL-37. J. Immunol. 176: 2455-2464 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»